Levofolinate

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Pancreatic CancerColorectal CancerGastric CancerMetastatic Colorectal CancerGastroesophageal Junction Adenocarcinoma

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

1

Levofolinate

Ono Pharmaceutical Co. Ltd

Phase 2

22

Gemzar

GGynecologic Oncology Group

Preclinical

1083

MS Contin

Merck & Co.

Preclinical

14

Feraheme

AAzurity Pharmaceuticals

Preclinical

15

ABI-007

Bristol-Myers Squibb

Preclinical

26

Active Comparator

Moderna

Preclinical

17

LDE225

Novartis

Preclinical

18

Sulfonylureas

Eli Lilly

Preclinical

19

Thiazolidinediones

Sanofi

Preclinical

110

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Completed·Ono Pharmaceutical Co. Ltd·Phase 1·NCT06538207·46 enrolled

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting·Ono Pharmaceutical Co. Ltd·Phase 1·NCT06532344·32 enrolled

Metastatic Colorectal Cancer2 trials

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Completed·Sanofi·Phase 2·NCT01882868·62 enrolled

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Completed·SSumitomo Pharma Co., Ltd.·Phase 1·NCT02641873·4 enrolled

Gastric Cancer1 trial

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Active, not recruiting·NNational Cancer Center Hospital East·Phase 2·NCT04745988·43 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Recruiting·NNational Cancer Center Hospital East·Phase 2·NCT07018570·26 enrolled

Fluorouracil1 trial

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Completed·Eli Lilly·Phase 1·NCT01286818·6 enrolled

1 more indication

Colorectal Cancer1 trial

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Active, not recruiting·Ono Pharmaceutical Co. Ltd·Phase 1·NCT06540261·65 enrolled

Details

Drug Info

Related News